Isis Soars on Cholesterol-Drug News

Investors bid the shares higher Monday after a study showed that one of its compounds cuts LDL levels -- and can be used in higher doses

Drugmakers appear to be taking steps forward in their battle to save people from unhealthy levels of cholesterol. Isis Pharmaceuticals (ISIS) shares surged more than 26% Nov. 13 after the company announced positive results in two studies of its cholesterol drug "ISIS 301012."

To continue reading this article you must be a Bloomberg Professional Service Subscriber.